HB 3318 expands access to investigational treatments for patients with life-threatening or severely debilitating illnesses. It creates a new chapter in the Health and Safety Code to allow eligible patients to receive individualized investigational treatments, such as gene therapy and other personalized medical interventions, without requiring full FDA approval. The bill establishes criteria for patient eligibility, informed consent procedures, and protections against liability for healthcare providers. It also prohibits state agencies from interfering with a patient’s access to these treatments and clarifies that insurance companies are not required to cover the associated costs​.